These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29674766)

  • 1. The Combination of Gemcitabine, Cisplatin, and Paclitaxel as Salvage Chemotherapy for Advanced Urothelial Carcinoma.
    Hirata T; Hanamoto M; Ogura K; Hayashi N; Takamura K; Edamura K; Ebara S; Saika T
    Acta Med Okayama; 2018 Apr; 72(2):175-179. PubMed ID: 29674766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
    Park JH; Lee JL
    Cancer Chemother Pharmacol; 2015 Feb; 75(2):247-54. PubMed ID: 25428517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II Study of Second-line Chemotherapy With Paclitaxel, Gemcitabine, and Cisplatin for Advanced Urothelial Carcinoma.
    Ogawa M; Yamamoto S; Inoue T; Numao N; Yuasa T; Masuda H; Fukui I; Yonese J
    Anticancer Res; 2020 Mar; 40(3):1613-1618. PubMed ID: 32132064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combination chemotherapy of paclitaxel, carboplatin and gemcitabine in patients who have received prior cisplatin-based chemotherapy].
    Ito H; Aoki Y; Oyama N; Miwa Y; Akino H; Yokoyama O
    Gan To Kagaku Ryoho; 2011 Mar; 38(3):481-4. PubMed ID: 21403460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
    Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
    Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen.
    Takahashi T; Higashi S; Nishiyama H; Segawa T; Nakamura E; Kinoshita H; Itoh N; Yamamoto S; Kamoto T; Habuchi T; Ogawa O
    Jpn J Clin Oncol; 2006 Feb; 36(2):104-8. PubMed ID: 16418182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma.
    Geldart T; Chester J; Casbard A; Crabb S; Elliott T; Protheroe A; Huddart RA; Mead G; Barber J; Jones RJ; Smith J; Cowles R; Evans J; Griffiths G
    Eur Urol; 2015 Apr; 67(4):599-602. PubMed ID: 25465968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis.
    Miyata Y; Nomata K; Ohba K; Matsuo T; Sagara Y; Kanetake H; Sakai H
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):451-9. PubMed ID: 22864875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma.
    Matsumoto K; Irie A; Satoh T; Okazaki M; Iwamura M; Baba S
    Int J Urol; 2007 Nov; 14(11):1000-4; discussion 1004. PubMed ID: 17956525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
    Alva A; Daignault S; Smith DC; Hussain M
    Invest New Drugs; 2014 Feb; 32(1):188-94. PubMed ID: 24318901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome of paclitaxel and carboplatin as second-line chemotherapy for advanced urothelial carcinoma resistant to first-line therapy with gemcitabine and cisplatin.
    Terakawa T; Miyake H; Yokoyama N; Miyazaki A; Tanaka H; Inoue T; Fujisawa M
    Urol Int; 2014; 92(2):180-5. PubMed ID: 24246751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy.
    Kanai K; Kikuchi E; Ohigashi T; Miyajima A; Nakagawa K; Nakashima J; Oya M
    Int J Clin Oncol; 2008 Dec; 13(6):510-4. PubMed ID: 19093178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of paclitaxel, cisplatin, and gemcitabine as first-line chemotherapy in cisplatin-fit and -unfit patients with advanced/metastatic urothelial carcinoma.
    Katayama S; Kobayashi Y; Takamoto A; Edamura K; Sadahira T; Iwata T; Nishimura S; Sako T; Wada K; Araki M; Watanabe M; Watanabe T; Nasu Y
    Urol Oncol; 2021 Oct; 39(10):731.e25-731.e32. PubMed ID: 33775531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.
    Sonpavde G; Pond GR; Choueiri TK; Mullane S; Niegisch G; Albers P; Necchi A; Di Lorenzo G; Buonerba C; Rozzi A; Matsumoto K; Lee JL; Kitamura H; Kume H; Bellmunt J
    Eur Urol; 2016 Apr; 69(4):634-641. PubMed ID: 26264159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma.
    Urakami S; Fujii Y; Yamamoto S; Yuasa T; Kitsukawa S; Sakura M; Yano A; Saito K; Masuda H; Yonese J; Fukui I
    Urol Oncol; 2014 Jan; 32(1):35.e1-7. PubMed ID: 23562233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine plus nedaplatin as salvage therapy is a favorable option for patients with progressive metastatic urothelial carcinoma after two lines of chemotherapy.
    Matsumoto K; Mochizuki K; Hirayama T; Ikeda M; Nishi M; Tabata K; Okazaki M; Fujita T; Taoka Y; Iwamura M
    Asian Pac J Cancer Prev; 2015; 16(6):2483-7. PubMed ID: 25824784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
    Bellmunt J; Albanell J; Paz-Ares L; Climent MA; González-Larriba JL; Carles J; de la Cruz JJ; Guillem V; Díaz-Rubio E; Cortés-Funes H; Baselga J;
    Cancer; 2002 Aug; 95(4):751-7. PubMed ID: 12209718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.
    Oing C; Rink M; Oechsle K; Seidel C; von Amsberg G; Bokemeyer C
    J Urol; 2016 Feb; 195(2):254-63. PubMed ID: 26410730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Third-line gemcitabine monotherapy for platinum-resistant advanced urothelial cancer.
    Soga N; Kise H; Arima K; Sugimura Y
    Int J Clin Oncol; 2010 Aug; 15(4):376-81. PubMed ID: 20333430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy.
    Shinohara N; Harabayashi T; Suzuki S; Nagao K; Seki H; Murakumo M; Mitsuhashi K; Demura T; Nagamori S; Matsuyama H; Naito K; Nonomura K
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):402-7. PubMed ID: 16416335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.